The data support the view that immunogenicity of tumor antigen T-cell epitopes strongly influences the duration of an anti-PD1/PD-L1 induced immune checkpoint blockade, and thus is an important parameter in determining the outcome of an immune checkpoint blockade therapy. Here, CD274 is linked to neoplasm.